“Given the expanding uncertainty with the case law on U.S. patents—and whether, for example, they’ll protect the subject matter of a million (or even billion) dollar investment—U.S. investment in R&D has dropped. And perhaps most notably, it has dropped among innovative bio-pharmaceutical companies.”